SARS-CoV-2 infection enhancement by amphotericin B: implications for disease management.
Nguyen D. et al, (2025), J Virol
A systems biology approach to define SARS-CoV-2 correlates of protection.
Brady C. et al, (2025), NPJ vaccines, 10
Detection of mpox and other orthopoxviruses using a lateral flow device as a point-of-care diagnostic.
Laidlaw SM. et al, (2025), Microbiology spectrum, 13
Silaproline-bearing nirmatrelvir derivatives are potent inhibitors of the SARS-CoV-2 main protease highlighting the value of silicon-derivatives in structure-activity-relationship studies.
Laczi D. et al, (2025), European journal of medicinal chemistry, 291
Complement-mediated enhancement of SARS-CoV-2 antibody neutralisation potency in vaccinated individuals.
Mellors J. et al, (2025), Nature communications, 16
Using minor variant genomes and machine learning to study the genome biology of SARS-CoV-2 over time.
Dong X. et al, (2025), Nucleic acids research, 53
Host-pathogen interactions of emerging zoonotic viruses: bats, humans and filoviruses.
Hood G. and Carroll M., (2024), Current opinion in virology
Therapeutics for Nipah virus disease: a systematic review to support prioritisation of drug candidates for clinical trials
Chan XHS. et al, (2024), The Lancet Microbe, 101002 - 101002
Performance of an envelope glycoprotein-based multiplex immunoassay for Ebola virus antibody detection in a cohort of Ebola virus disease survivors.
Roe MD. et al, (2024), Journal of virological methods, 331
Obesity differs from diabetes mellitus in antibody and T-cell responses post-COVID-19 recovery
Ali M. et al, (2024), Clinical and Experimental Immunology, 218, 78 - 92
Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy.
Lim YJ. et al, (2024), British journal of haematology, 205, 440 - 451
Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study
Jackson S. et al, (2024), The Lancet Microbe, 5, 655 - 668
Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial.
Goodyear CS. et al, (2024), The Lancet. Rheumatology, 6, e339 - e351
Structural and functional characterization of nanobodies that neutralize Omicron variants of SARS-CoV-2.
Cornish K. et al, (2024), Open biology, 14
Serological evidence of zoonotic filovirus exposure among bushmeat hunters in Guinea.
Akoi Boré J. et al, (2024), Nature communications, 15
Direct enhancement of viral neutralising antibody potency by the complement system: a largely forgotten phenomenon.
Mellors J. and Carroll M., (2024), Cellular and molecular life sciences : CMLS, 81
Serum HCoV-spike specific antibodies do not protect against subsequent SARS-CoV-2 infection in children and adolescents
Ratcliffe H. et al, (2023), iScience, 26, 108500 - 108500
Immune responses and clinical outcomes after COVID-19 vaccination in patients with liver disease and liver transplant recipients.
Murray SM. et al, (2023), Journal of hepatology
A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2.
Wilkinson T. et al, (2023), ERJ open research, 9, 249 - 2023
Cellular immunity to SARS-CoV-2 following intrafamilial exposure in seronegative family members
Jay C. et al, (2023), Frontiers in Immunology, 14
Omicron infection following vaccination enhances a broad spectrum of immune responses dependent on infection history
Hornsby H. et al, (2023), Nature Communications, 14
Corrigendum: Inhibition of phosphodiesterase 12 results in antiviral activity against several RNA viruses including SARS-CoV-2.
Thursz M. et al, (2023), The Journal of general virology, 104
Establishing SARS-CoV-2 membrane protein-specific antibodies as a valuable serological target via high-content microscopy.
Williams DM. et al, (2023), iScience, 26
Inhibition of phosphodiesterase 12 results in antiviral activity against several RNA viruses including SARS-CoV-2.
Thursz M. et al, (2023), The Journal of general virology, 104
Evaluation of QuantiFERON SARS-CoV-2 interferon-γ release assay following SARS-CoV-2 infection and vaccination
Johnson SA. et al, (2023), Clinical and Experimental Immunology, 212, 249 - 261
Mammalian expression systems and vaccination
Carroll MW. et al, (2023), Genetically Engineered Viruses: Development and Applications, 107 - 157
Linked Mutations in the Ebola Virus Polymerase Are Associated with Organ Specific Phenotypes.
Dong X. et al, (2023), Microbiol Spectr
Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens
Moore SC. et al, (2023), Med, 4, 191 - 215.e9
Alkyne Derivatives of SARS-CoV-2 Main Protease Inhibitors Including Nirmatrelvir Inhibit by Reacting Covalently with the Nucleophilic Cysteine
Brewitz L. et al, (2023), Journal of Medicinal Chemistry, 66, 2663 - 2680
Identification of novel antiviral drug candidates using an optimized SARS-CoV-2 phenotypic screening platform.
Bojkova D. et al, (2023), iScience, 26
Influence of Landscape Patterns on Exposure to Lassa Fever Virus, Guinea.
Longet S. et al, (2023), Emerging infectious diseases, 29, 304 - 313
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus
Fidler S. et al, (2023), Clinical Infectious Diseases, 76, 201 - 209
Age- and sex-specific differences in immune responses to BNT162b2 COVID-19 and live-attenuated influenza vaccines in UK adolescents.
Jay C. et al, (2023), Frontiers in immunology, 14
Pre-clinical models to define correlates of protection for SARS-CoV-2.
Brady C. et al, (2023), Frontiers in immunology, 14
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial.
Donovan-Banfield I. et al, (2022), Nat Commun, 13
An introduction to the Marburg virus vaccine consortium, MARVAC.
Cross RW. et al, (2022), PLoS pathogens, 18
Avatar Mice Underscore the Role of the T Cell-Dendritic Cell Crosstalk in Ebola Virus Disease and Reveal Mechanisms of Protection in Survivors.
Rottstegge M. et al, (2022), Journal of virology
Hypoxia inducible factors regulate infectious SARS-CoV-2, epithelial damage and respiratory symptoms in a hamster COVID-19 model.
Wing PAC. et al, (2022), PLoS pathogens, 18
A prototype lateral flow assay for detection of orthopoxviruses.
Ulaeto DO. et al, (2022), The Lancet. Infectious diseases, 22, 1279 - 1280
Evolutionary implications of human transmission of monkeypox: the importance of sequencing multiple lesions.
Ulaeto DO. et al, (2022), The Lancet. Microbe, 3, e639 - e640
Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses
McNaughton AL. et al, (2022), JCI Insight, 7
Convalescent plasma donors show enhanced cross-reactive neutralizing antibody response to antigenic variants of SARS-CoV-2 following immunization.
Harvala H. et al, (2022), Transfusion, 62, 1347 - 1354
SARS-CoV-2-Specific T Cell Responses Are Not Associated with Protection against Reinfection in Hemodialysis Patients
Shankar S. et al, (2022), Journal of the American Society of Nephrology, 33, 883 - 887
Synthetic Heparan Sulfate Mimetic Pixatimod (PG545) Potently Inhibits SARS-CoV-2 by Disrupting the Spike-ACE2 Interaction.
Guimond SE. et al, (2022), ACS central science, 8, 527 - 545
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
Ogbe A. et al, (2022), JCI Insight, 7
Ribavirin for treating Lassa fever: A systematic review of pre-clinical studies and implications for human dosing
Salam AP. et al, (2022), PLOS Neglected Tropical Diseases, 16, e0010289 - e0010289